NPCE
$13.82
NeuroPace, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant fo...
Recent News
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
Why NeuroPace Stock Was Inching Higher on Wednesday
The company finished 2025 with a convincing pair of earnings beats.
NeuroPace Inc (NPCE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
NeuroPace Inc (NPCE) reports robust revenue growth and positive EBITDA, while navigating challenges and advancing its AI-driven product pipeline.